首页> 外文期刊>Pediatric Hematology and Oncology >Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
【24h】

Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.

机译:恩丹西酮和tropisetron在控制接受联合化疗的儿童的恶心和呕吐中的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Ondansetron (Zofron, Glaxo) and tropisetron (Navoban, Sandoz) are selective serotonin (5HT3) antagonists that have proven very effective in the prevention of vomiting and nausea in adults and children receiving cancer chemotherapy. This study compared the efficacy of the two agents in the prevention of vomiting and nausea in children receiving chemotherapy for solid tumors and blood malignancies. A total of 23 children were studied in 205 chemotherapeutic cycles (116 one-day regimens and 89 multiple-day regimens). In 102 chemotherapeutic cycles the children received ondansetron as an antiemetic agent in a dose of 5 mg/m2 30 min before chemotherapy was given and then 4 mg/m2 every 8 h i.v. (group A) and in 103 cycles they received tropisetron in one dose of 0.2 mg/kg 24 h-1 i.v. (max dose 5 mg) 30 min before cytotoxic drugs administration every day they received chemotherapy (group B). The response was defined as complete in the absence of nausea and vomiting per 24 h of chemotherapy, as partial given the presence of 1-4 events of vomiting and/or nausea less than 5 h per 24 h, and as failure if there were more than 4 events of vomiting and/or nausea for more than 5 h per 24 h of chemotherapy. The response of the two groups was studied independently and depending on the degree of emetogenicity of the chemotherapeutic agents, which were divided into mildly, moderately, and highly emetogenic. The comparison of the two groups not taking into consideration the emetogenicity of the chemotherapeutic agents showed that ondansetron was more effective in 1-day regimens (P = .023), whereas the two agents were equally effective in multiple-day regimens (P = .2). The statistical analysis depending on the emetogenicity of the chemotherapeutic agents showed increased efficacy of ondansetron in mild (P = .017) and moderately emetogenic chemotherapeutic agents, whereas there was no difference in the highly emetogenic drug group. Ondansetron is found to be more effective than tropisetron in controlling acute nausea and vomiting in children receiving mild and moderately emetogenic chemotherapeutic drugs, although there is no difference in the efficacy of both antiemetic agents when highly emetogenic drugs are administered.
机译:恩丹西酮(Zofron,Glaxo)和tropisetron(Navoban,Sandoz)是选择性5-羟色胺(5HT3)拮抗剂,已被证明对预防癌症化疗的成人和儿童的呕吐和恶心非常有效。这项研究比较了两种药物预防实体瘤和血液恶性肿瘤接受化疗的儿童呕吐和恶心的功效。在205个化疗周期(116个一日方案和89个多日方案)中研究了23名儿童。在102个化学治疗周期中,儿童在接受化疗前30分钟以5 mg / m2的剂量服用恩丹西酮作为止吐剂,然后每8 h静脉注射4 mg / m2。 (A组),在103个周期中,他们接受了剂量为0.2 mg / kg 24 h-1 i.v.的tropisetron。 (最大剂量5 mg)每天在细胞毒性药物给药前30分钟接受化疗(B组)。定义为:每24 h化疗中无恶心和呕吐的情况下完成反应;每24 h少于5 h出现1-4次呕吐和/或恶心事件,则定义为部分反应;如果有更多反应,则定义为失败每24小时化疗中有4次以上呕吐和/或恶心事件超过5小时。分别对两组的反应进行了研究,具体取决于化学治疗剂的致呕程度,分为轻度,中度和高度致呕作用。两组未考虑化疗药物致癌性的比较表明,恩丹西酮在1天方案中更有效(P = .023),而两种药物在多日方案中同样有效(P =。 2)。根据化学治疗剂的致癌性进行的统计分析表明,恩丹西酮在轻度(P = .017)和中度致癌的化学治疗剂中的疗效增加,而高致呕吐的药物组没有差异。恩丹西酮在控制轻度和中度催吐药的儿童中,在控制急性恶心和呕吐方面比托吡司通更有效,尽管在服用高度催吐药时两种止吐药的疗效没有差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号